These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 20682372

  • 1. Bisphosphonates in lung cancer: more than a palliative therapy?
    Jahanzeb M, Hirsh V.
    Semin Oncol; 2010 Jun; 37 Suppl 1():S45-52. PubMed ID: 20682372
    [Abstract] [Full Text] [Related]

  • 2. Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer.
    Hirsh V.
    Clin Lung Cancer; 2009 Jul; 10(4):223-9. PubMed ID: 19632938
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
    Facchini G, Caraglia M, Santini D, Nasti G, Ottaiano A, Striano S, Maiolino P, Ruberto M, Fiore F, Tonini G, Budillon A, Iaffaioli RV, Zeppetella GL.
    J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Emerging strategies in bone health management for the adjuvant patient.
    Coleman RE.
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S11-6. PubMed ID: 18068485
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
    Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ.
    J Clin Oncol; 2003 Aug 15; 21(16):3150-7. PubMed ID: 12915606
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Zoledronic acid in lung cancer with bone metastases: a review.
    Isla D, Afonso R, Bosch-Barrera J, Martínez N.
    Expert Rev Anticancer Ther; 2013 Apr 15; 13(4):421-6. PubMed ID: 23560837
    [Abstract] [Full Text] [Related]

  • 12. The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer.
    Mahtani R, Khan R, Jahanzeb M.
    Clin Lung Cancer; 2011 Jan 15; 12(1):26-32. PubMed ID: 21273176
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Recommendations for zoledronic acid treatment of patients with bone metastases.
    Berenson JR.
    Oncologist; 2005 Jan 15; 10(1):52-62. PubMed ID: 15632252
    [Abstract] [Full Text] [Related]

  • 16. Burden of bone disease.
    Kinnane N.
    Eur J Oncol Nurs; 2007 Jan 15; 11 Suppl 2():S28-31. PubMed ID: 17768092
    [Abstract] [Full Text] [Related]

  • 17. Zoledronic acid: multiplicity of use across the cancer continuum.
    Lipton A.
    Expert Rev Anticancer Ther; 2011 Jul 15; 11(7):999-1012. PubMed ID: 21806323
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.
    J Med Econ; 2012 Jul 15; 15(4):712-23. PubMed ID: 22409231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.